The
CAR-T (termed B4T2-001) is an investigational therapeutic designed to recognize the antigen BT-001 overexpressed on the surface of multiple types of solid tumors. You may be eligible if you have advanced solid tumors such as gastric or gastroesophageal junction adenocarcinoma, pancreatic cancer, non-small cell lung cancer and breast cancer. Before enrollment you will be tested to determine if your cancer expresses sufficient levels of BT-001.
Your CAR-T are generated by harvesting cells from your body using a technology termed apheresis. Circulating T cells are then genetically modified under controlled conditions in the laboratory to express a chimeric antigen receptor (CAR). This redirects the specificity of T cells for the target BT-001. After passing a checklist of tests, your CAR-T are infused. In follow up you will be closely monitored for safety and anti-tumor effects.
For more information, please email and include "Patient Clinical Trial Info" in the subject line.
